<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Melkersson-Rosenthal syndrome - Disorder Mechanisms</title>
    <style>
        :root {
            --primary: #0f766e;
            --primary-light: #14b8a6;
            --primary-dark: #0d5c56;
            --secondary: #6366f1;
            --bg: #f0fdfa;
            --card-bg: #ffffff;
            --text: #134e4a;
            --text-muted: #5f7a78;
            --border: #ccfbf1;
            --accent-orange: #f59e0b;
            --accent-rose: #f43f5e;
            --accent-violet: #8b5cf6;
            --accent-sky: #0ea5e9;
        }

        * { box-sizing: border-box; margin: 0; padding: 0; }

        body {
            font-family: 'Segoe UI', system-ui, -apple-system, sans-serif;
            background: var(--bg);
            color: var(--text);
            line-height: 1.7;
        }

        .container {
            max-width: 1100px;
            margin: 0 auto;
            padding: 24px;
        }

        /* Header */
        .page-header {
            background: linear-gradient(135deg, var(--primary) 0%, var(--primary-dark) 100%);
            color: white;
            padding: 40px 32px;
            border-radius: 16px;
            margin-bottom: 24px;
            position: relative;
            overflow: hidden;
        }

        .page-header::before {
            content: '';
            position: absolute;
            top: -50%;
            right: -20%;
            width: 400px;
            height: 400px;
            background: rgba(255,255,255,0.05);
            border-radius: 50%;
        }

        .page-header h1 {
            font-size: 2.2rem;
            font-weight: 700;
            margin-bottom: 12px;
            position: relative;
        }

        .header-meta {
            display: flex;
            flex-wrap: wrap;
            gap: 12px;
            align-items: center;
            position: relative;
        }

        .badge {
            display: inline-flex;
            align-items: center;
            padding: 6px 14px;
            border-radius: 20px;
            font-size: 0.85rem;
            font-weight: 500;
        }

        .badge-category {
            background: rgba(255,255,255,0.2);
            color: white;
        }

        .badge-mondo {
            background: var(--accent-sky);
            color: white;
        }

        .badge-mondo a {
            color: inherit;
            text-decoration: none;
        }

        .badge-mondo a:hover {
            text-decoration: underline;
        }

        /* Navigation */
        .breadcrumb {
            margin-bottom: 16px;
            font-size: 0.9rem;
        }

        .breadcrumb a {
            color: var(--primary);
            text-decoration: none;
        }

        .breadcrumb a:hover {
            text-decoration: underline;
        }

        .breadcrumb span {
            color: var(--text-muted);
        }

        /* Cards */
        .card {
            background: var(--card-bg);
            border-radius: 12px;
            border: 1px solid var(--border);
            padding: 24px;
            margin-bottom: 20px;
            box-shadow: 0 1px 3px rgba(0,0,0,0.04);
        }

        .card-header {
            display: flex;
            align-items: center;
            gap: 12px;
            margin-bottom: 16px;
            padding-bottom: 12px;
            border-bottom: 2px solid var(--border);
        }

        .card-icon {
            width: 36px;
            height: 36px;
            border-radius: 8px;
            display: flex;
            align-items: center;
            justify-content: center;
            font-size: 1.2rem;
        }

        .card-title {
            font-size: 1.1rem;
            font-weight: 600;
            color: var(--text);
        }

        .card-count {
            margin-left: auto;
            background: var(--bg);
            padding: 4px 12px;
            border-radius: 12px;
            font-size: 0.8rem;
            color: var(--text-muted);
        }

        /* Sections */
        .section-grid {
            display: grid;
            grid-template-columns: repeat(auto-fit, minmax(320px, 1fr));
            gap: 20px;
        }

        /* Tags */
        .tag-list {
            display: flex;
            flex-wrap: wrap;
            gap: 8px;
        }

        .tag {
            padding: 6px 12px;
            border-radius: 6px;
            font-size: 0.85rem;
            font-weight: 500;
        }

        .tag-cell {
            background: #fce7f3;
            color: #9d174d;
        }

        .tag-gene {
            background: #dbeafe;
            color: #1e40af;
        }

        .tag-treatment {
            background: #ede9fe;
            color: #5b21b6;
        }

        .tag-env {
            background: #ccfbf1;
            color: #0f766e;
        }

        .tag-location {
            background: #e0e7ff;
            color: #3730a3;
        }

        .tag-component {
            background: #f0fdf4;
            color: #166534;
        }

        .tag-complex {
            background: #faf5ff;
            color: #7e22ce;
        }

        .tag-bio {
            background: #fef3c7;
            color: #92400e;
        }

        .tag-modifier {
            background: #fee2e2;
            color: #991b1b;
            text-transform: uppercase;
            letter-spacing: 0.02em;
        }

        .tag-parent {
            background: #e0e7ff;
            color: #3730a3;
        }

        .tag-classification {
            background: #fef3c7;
            color: #92400e;
        }

        .tag-mechanistic {
            background: #dbeafe;
            color: #1e40af;
        }

        .linkout {
            color: inherit;
            margin-left: 6px;
            font-size: 0.75rem;
            text-decoration: none;
            border-bottom: 1px dotted rgba(0, 0, 0, 0.2);
        }

        .classification-category {
            font-size: 0.75rem;
            font-weight: 600;
            text-transform: uppercase;
            letter-spacing: 0.05em;
            color: var(--text-muted);
            margin-bottom: 8px;
        }

        .mapping-section {
            margin-bottom: 16px;
        }

        .mapping-item {
            padding: 10px 12px;
            border: 1px solid #e2e8f0;
            border-radius: 8px;
            background: #ffffff;
            margin-bottom: 10px;
        }

        .mapping-title {
            font-size: 0.9rem;
            font-weight: 600;
            display: flex;
            flex-wrap: wrap;
            gap: 8px;
            align-items: baseline;
            margin-bottom: 6px;
        }

        .mapping-label {
            color: var(--text-muted);
            font-weight: 500;
        }

        .mapping-notes {
            font-size: 0.85rem;
            color: var(--text-muted);
            margin-top: 6px;
        }

        .mapping-tree {
            margin-top: 6px;
            font-size: 0.75rem;
            color: var(--text-muted);
            list-style: none;
            padding-left: 0;
        }

        .mapping-tree li {
            margin: 2px 0;
        }

        /* Evidence styling */
        .evidence-toggle {
            cursor: pointer;
            font-size: 0.8rem;
            color: var(--text-muted);
            margin-top: 10px;
            user-select: none;
        }

        .evidence-toggle:hover {
            color: var(--primary);
        }

        .evidence-list {
            margin-top: 10px;
            padding-left: 0;
        }

        .evidence-item {
            padding: 12px 14px;
            background: #f8fafc;
            border-radius: 8px;
            margin-bottom: 8px;
            border: 1px solid #e2e8f0;
            font-size: 0.9rem;
        }

        .evidence-header {
            display: flex;
            align-items: center;
            flex-wrap: wrap;
            gap: 8px;
        }

        .evidence-ref {
            font-weight: 600;
            color: var(--secondary);
        }

        .evidence-ref a {
            color: inherit;
            text-decoration: none;
        }

        .evidence-ref a:hover {
            text-decoration: underline;
        }

        .evidence-support {
            font-size: 0.7rem;
            padding: 2px 8px;
            border-radius: 4px;
            font-weight: 600;
            text-transform: uppercase;
            transition: transform 120ms ease, box-shadow 120ms ease;
        }

        .support-SUPPORT { background: #dcfce7; color: #166534; }
        .support-PARTIAL { background: #fef3c7; color: #92400e; }
        .support-REFUTE { background: #fee2e2; color: #991b1b; }
        .support-NO_EVIDENCE { background: #f1f5f9; color: #64748b; }
        .support-WRONG_STATEMENT { background: #fecaca; color: #7f1d1d; }

        .evidence-source {
            font-size: 0.7rem;
            padding: 2px 8px;
            border-radius: 4px;
            font-weight: 600;
            text-transform: uppercase;
            background: #e2e8f0;
            color: #334155;
            transition: transform 120ms ease, box-shadow 120ms ease;
        }

        .evidence-support:hover,
        .evidence-source:hover {
            transform: translateY(-1px);
            box-shadow: 0 4px 10px rgba(0,0,0,0.08);
        }

        .source-HUMAN_CLINICAL { background: #e0f2fe; color: #075985; }
        .source-MODEL_ORGANISM { background: #fef9c3; color: #854d0e; }
        .source-IN_VITRO { background: #ede9fe; color: #5b21b6; }
        .source-COMPUTATIONAL { background: #cffafe; color: #0e7490; }
        .source-OTHER { background: #e5e7eb; color: #374151; }

        .evidence-snippet {
            font-size: 0.85rem;
            color: var(--text-muted);
            margin-top: 8px;
            padding-left: 12px;
            border-left: 2px solid #cbd5e1;
            font-style: italic;
            line-height: 1.5;
        }

        .evidence-explanation {
            font-size: 0.85rem;
            color: var(--text);
            margin-top: 6px;
            line-height: 1.5;
        }

        .evidence-more {
            font-size: 0.8rem;
            color: var(--text-muted);
            margin-top: 6px;
            font-style: italic;
        }

        .findings-section {
            margin-top: 12px;
        }

        .findings-title {
            font-size: 0.75rem;
            font-weight: 600;
            text-transform: uppercase;
            letter-spacing: 0.04em;
            color: var(--text-muted);
            margin-bottom: 6px;
        }

        .finding-item {
            padding: 10px 12px;
            background: #f8fafc;
            border-radius: 8px;
            margin-bottom: 8px;
            border: 1px solid #e2e8f0;
            font-size: 0.9rem;
        }

        .finding-statement {
            font-weight: 600;
            color: var(--text);
            margin-bottom: 6px;
            line-height: 1.5;
        }

        .finding-supporting {
            font-size: 0.85rem;
            color: var(--text-muted);
            margin-top: 6px;
            padding-left: 12px;
            border-left: 2px solid #cbd5e1;
            font-style: italic;
            line-height: 1.5;
        }

        /* Item containers with evidence */
        .item-box {
            padding: 16px;
            border-radius: 10px;
            margin-bottom: 12px;
        }

        .item-name {
            font-weight: 600;
            margin-bottom: 6px;
        }

        .item-desc {
            font-size: 0.9rem;
            line-height: 1.6;
            margin-bottom: 8px;
        }

        .item-meta {
            display: flex;
            flex-wrap: wrap;
            gap: 6px;
            margin-top: 8px;
        }

        /* Definitions */
        .definition-box {
            background: #ecfeff;
            border-left: 4px solid #0ea5e9;
        }
        .definition-box .item-name { color: #0c4a6e; }
        .definition-box .item-desc { color: #075985; }

        /* Inheritance */
        .inheritance-box {
            background: #fef9c3;
            border-left: 4px solid #ca8a04;
        }
        .inheritance-box .item-name { color: #92400e; }
        .inheritance-box .item-desc { color: #92400e; }

        .criteria-block {
            margin-top: 12px;
            padding: 12px;
            border-radius: 8px;
            border: 1px solid #bae6fd;
            background: rgba(255, 255, 255, 0.7);
        }

        .criteria-title {
            font-weight: 600;
            color: #0c4a6e;
            margin-bottom: 6px;
        }

        .criteria-meta {
            font-size: 0.8rem;
            color: var(--text-muted);
            margin-bottom: 8px;
        }

        .criteria-header {
            font-size: 0.75rem;
            text-transform: uppercase;
            letter-spacing: 0.04em;
            color: #0284c7;
            margin-top: 8px;
        }

        .criteria-list {
            margin-left: 18px;
            font-size: 0.9rem;
            line-height: 1.5;
            color: #0f172a;
        }

        .criteria-list li {
            margin-bottom: 6px;
        }

        .criteria-detail {
            display: block;
            font-size: 0.85rem;
            color: var(--text-muted);
        }

        /* Pathophysiology */
        .pathophys-box {
            background: linear-gradient(135deg, #fef3c7 0%, #fef9c3 100%);
            border-left: 4px solid var(--accent-orange);
        }
        .pathophys-box .item-name { color: #92400e; }
        .pathophys-box .item-desc { color: #78350f; }

        /* Histopathology */
        .histopathology-box {
            background: #fff7ed;
            border-left: 4px solid #fb923c;
        }
        .histopathology-box .item-name { color: #9a3412; }
        .histopathology-box .item-desc { color: #c2410c; }

        .histopathology-freq {
            font-size: 0.75rem;
            padding: 2px 8px;
            border-radius: 10px;
            background: #ffedd5;
            color: #c2410c;
        }

        /* Phenotypes */
        .phenotype-box {
            background: #f0fdf4;
            border-left: 4px solid #22c55e;
        }
        .phenotype-box .item-name { color: #166534; }
        .phenotype-box .item-desc { color: #15803d; }

        .phenotype-freq {
            font-size: 0.75rem;
            padding: 2px 8px;
            border-radius: 10px;
            background: #dcfce7;
            color: #15803d;
        }

        .phenotype-category {
            font-size: 0.75rem;
            color: #4ade80;
        }

        .phenotype-id a {
            font-size: 0.8rem;
            color: var(--secondary);
            text-decoration: none;
        }

        .phenotype-id a:hover {
            text-decoration: underline;
        }

        /* Phenotype TOC strip */
        .pheno-toc {
            display: flex;
            flex-wrap: wrap;
            gap: 6px;
            padding: 10px 0 6px 0;
            border-bottom: 1px solid #e2e8f0;
            margin-bottom: 4px;
        }

        .pheno-toc-pill {
            display: inline-block;
            font-size: 0.78rem;
            padding: 3px 10px;
            border-radius: 12px;
            background: #dcfce7;
            color: #166534;
            text-decoration: none;
            cursor: pointer;
            white-space: nowrap;
            transition: background 0.15s;
        }

        .pheno-toc-pill:hover {
            background: #bbf7d0;
        }

        .pheno-toc-pill .pill-count {
            font-weight: 600;
            margin-left: 2px;
        }

        .pheno-toggle-all {
            font-size: 0.78rem;
            color: #16a34a;
            cursor: pointer;
            background: none;
            border: 1px solid #bbf7d0;
            border-radius: 6px;
            padding: 3px 10px;
            margin-left: auto;
            white-space: nowrap;
            transition: background 0.15s;
        }

        .pheno-toggle-all:hover {
            background: #f0fdf4;
        }

        /* Collapsible category groups */
        .phenotype-category-group {
            margin-bottom: 2px;
        }

        .phenotype-category-group summary {
            font-size: 0.85rem;
            font-weight: 600;
            text-transform: uppercase;
            letter-spacing: 0.04em;
            color: #16a34a;
            margin: 0;
            padding: 10px 0 6px 0;
            border-bottom: 1px solid #bbf7d0;
            cursor: pointer;
            list-style: none;
            display: flex;
            align-items: center;
            gap: 6px;
        }

        .phenotype-category-group summary::-webkit-details-marker {
            display: none;
        }

        .phenotype-category-group summary .chevron {
            display: inline-block;
            width: 16px;
            height: 16px;
            transition: transform 0.15s;
            flex-shrink: 0;
        }

        .phenotype-category-group[open] summary .chevron {
            transform: rotate(90deg);
        }

        .phenotype-category-group summary .cat-count {
            font-size: 0.75rem;
            font-weight: 400;
            color: #15803d;
            background: #dcfce7;
            padding: 1px 7px;
            border-radius: 8px;
        }

        /* Phenotype Contexts */
        .phenotype-contexts {
            margin-top: 10px;
        }

        .phenotype-contexts-toggle {
            font-size: 0.8rem;
            color: var(--text-muted);
            cursor: pointer;
            user-select: none;
        }

        .phenotype-contexts-toggle:hover {
            color: var(--primary);
        }

        .context-card {
            padding: 10px 14px;
            margin-top: 8px;
            border-radius: 8px;
            background: #ecfdf5;
            border: 1px solid #a7f3d0;
            font-size: 0.88rem;
        }

        .context-header {
            display: flex;
            flex-wrap: wrap;
            align-items: center;
            gap: 6px;
            margin-bottom: 6px;
        }

        .context-label {
            font-size: 0.72rem;
            font-weight: 600;
            text-transform: uppercase;
            letter-spacing: 0.04em;
            padding: 2px 8px;
            border-radius: 4px;
        }

        .context-label-genetic {
            background: #dbeafe;
            color: #1e40af;
        }

        .context-label-sex {
            background: #fce7f3;
            color: #9d174d;
        }

        .context-label-population {
            background: #fef3c7;
            color: #92400e;
        }

        .context-label-age {
            background: #e0e7ff;
            color: #3730a3;
        }

        .context-label-subtype {
            background: #ede9fe;
            color: #5b21b6;
        }

        .context-label-frequency {
            background: #dcfce7;
            color: #166534;
        }

        .context-gene-list {
            display: flex;
            flex-wrap: wrap;
            gap: 4px;
            margin: 4px 0;
        }

        .context-gene-tag {
            font-size: 0.78rem;
            font-weight: 600;
            padding: 1px 8px;
            border-radius: 4px;
            background: #bfdbfe;
            color: #1e3a8a;
        }

        .context-detail {
            font-size: 0.84rem;
            color: #065f46;
            line-height: 1.5;
        }

        .context-detail strong {
            color: #047857;
        }

        .context-freq {
            font-size: 0.75rem;
            padding: 2px 8px;
            border-radius: 10px;
            background: #bbf7d0;
            color: #14532d;
            font-weight: 600;
        }

        .context-onset {
            font-size: 0.75rem;
            padding: 2px 8px;
            border-radius: 10px;
            background: #e0e7ff;
            color: #3730a3;
        }

        .context-severity {
            font-size: 0.75rem;
            padding: 2px 8px;
            border-radius: 10px;
            background: #fef3c7;
            color: #92400e;
        }

        .context-notes {
            font-size: 0.84rem;
            color: #065f46;
            margin-top: 4px;
            line-height: 1.5;
        }

        /* Genetic */
        .genetic-box {
            background: #eff6ff;
            border-left: 4px solid #3b82f6;
        }
        .genetic-box .item-name { color: #1e40af; }
        .genetic-box .item-desc { color: #2563eb; }

        /* Treatment */
        .treatment-box {
            background: #faf5ff;
            border-left: 4px solid #8b5cf6;
        }
        .treatment-box .item-name { color: #5b21b6; }
        .treatment-box .item-desc { color: #7c3aed; }

        /* Environmental */
        .environmental-box {
            background: #f0fdfa;
            border-left: 4px solid #14b8a6;
        }
        .environmental-box .item-name { color: #0f766e; }
        .environmental-box .item-desc { color: #0d9488; }

        /* Biochemical */
        .biochemical-box {
            background: #fffbeb;
            border-left: 4px solid #f59e0b;
        }
        .biochemical-box .item-name { color: #92400e; }
        .biochemical-box .item-desc { color: #b45309; }

        /* Differential Diagnoses */
        .differential-box {
            background: #fef2f2;
            border-left: 4px solid #dc2626;
        }
        .differential-box .item-name { color: #7f1d1d; }
        .differential-box .item-desc { color: #b91c1c; }

        .differential-similarities {
            background: #fee2e2;
            border-left: 2px solid #dc2626;
            padding: 10px 12px;
            border-radius: 6px;
            margin: 8px 0;
            font-size: 0.9rem;
        }

        .differential-distinctions {
            background: #dcfce7;
            border-left: 2px solid #16a34a;
            padding: 10px 12px;
            border-radius: 6px;
            margin: 8px 0;
            font-size: 0.9rem;
        }

        .differential-similarities strong,
        .differential-distinctions strong {
            display: block;
            margin-bottom: 6px;
            font-size: 0.85rem;
            text-transform: uppercase;
            letter-spacing: 0.05em;
        }

        .differential-similarities ul,
        .differential-distinctions ul {
            margin-left: 16px;
            line-height: 1.6;
        }

        .differential-similarities li,
        .differential-distinctions li {
            margin: 4px 0;
            font-size: 0.9rem;
        }

        /* Datasets */
        .dataset-box {
            background: #f0f9ff;
            border-left: 4px solid #0284c7;
        }
        .dataset-box .item-name { color: #0c4a6e; }
        .dataset-box .item-desc { color: #0369a1; }

        .tag-dataset {
            background: #e0f2fe;
            color: #0369a1;
        }

        .tag-organism {
            background: #fae8ff;
            color: #a21caf;
        }

        .tag-datatype {
            background: #dbeafe;
            color: #1d4ed8;
        }

        /* Clinical Trials */
        .clinical-trial-box {
            background: #f5f3ff;
            border-left: 4px solid #a855f7;
        }
        .clinical-trial-box .item-name { color: #6b21a8; }
        .clinical-trial-box .item-desc { color: #7e22ce; }

        .tag-phase {
            background: #ede9fe;
            color: #6b21a8;
        }

        .tag-status {
            background: #fce7f3;
            color: #9d174d;
        }

        .trial-nct a {
            font-family: 'Fira Code', 'Consolas', monospace;
            font-size: 0.85rem;
            color: var(--secondary);
            text-decoration: none;
        }

        .trial-nct a:hover {
            text-decoration: underline;
        }

        .dataset-accession a {
            font-family: 'Fira Code', 'Consolas', monospace;
            font-size: 0.85rem;
            color: var(--secondary);
            text-decoration: none;
        }

        .dataset-accession a:hover {
            text-decoration: underline;
        }

        /* Subtypes */
        .subtype-box {
            background: #eef2ff;
            border-left: 4px solid var(--secondary);
        }
        .subtype-box .item-name { color: #3730a3; }
        .subtype-box .item-desc { color: #4f46e5; }
        .classification-header {
            font-size: 1rem;
            font-weight: 600;
            color: #4338ca;
            margin: 1.2rem 0 0.5rem 0;
            padding-bottom: 0.3rem;
            border-bottom: 2px solid #c7d2fe;
            text-transform: capitalize;
        }
        .subtype-meta {
            display: flex;
            flex-wrap: wrap;
            gap: 0.4rem;
            margin: 0.3rem 0;
        }
        .subtype-freq-badge {
            background: #dbeafe;
            color: #1e40af;
            padding: 0.15rem 0.5rem;
            border-radius: 9999px;
            font-size: 0.8rem;
            font-weight: 500;
        }
        .subtype-gene-tag {
            background: #fef3c7;
            color: #92400e;
            padding: 0.15rem 0.5rem;
            border-radius: 9999px;
            font-size: 0.8rem;
            font-weight: 500;
        }
        .subtype-inheritance-tag {
            background: #ede9fe;
            color: #5b21b6;
            padding: 0.15rem 0.5rem;
            border-radius: 9999px;
            font-size: 0.8rem;
            font-weight: 500;
        }
        .subtype-term-link {
            font-size: 0.8rem;
            color: #6366f1;
            text-decoration: none;
        }
        .subtype-term-link:hover { text-decoration: underline; }
        .subtype-children {
            margin: 0.4rem 0 0.2rem 1rem;
            padding: 0;
            list-style: none;
        }
        .subtype-children li {
            font-size: 0.85rem;
            color: #4338ca;
            padding: 0.1rem 0;
        }
        .subtype-children li::before {
            content: "↳ ";
            color: #a5b4fc;
        }

        /* Stats bar */
        .stats-bar {
            display: flex;
            gap: 24px;
            padding: 20px 24px;
            background: var(--card-bg);
            border-radius: 12px;
            border: 1px solid var(--border);
            margin-bottom: 24px;
            flex-wrap: wrap;
        }

        .stat-item {
            text-align: center;
        }

        .stat-link {
            text-decoration: none;
            color: inherit;
        }

        .stat-value {
            font-size: 1.5rem;
            font-weight: 700;
            color: var(--primary);
        }

        .stat-label {
            font-size: 0.8rem;
            color: var(--text-muted);
            text-transform: uppercase;
            letter-spacing: 0.05em;
        }

        /* YAML preview */
        .yaml-preview {
            background: #1e293b;
            color: #e2e8f0;
            padding: 20px;
            border-radius: 8px;
            overflow-x: auto;
            font-family: 'Fira Code', 'Consolas', monospace;
            font-size: 0.85rem;
            line-height: 1.5;
            max-height: 400px;
            overflow-y: auto;
        }

        .yaml-content {
            display: none;
        }

        .yaml-content.show {
            display: block;
        }

        /* Footer */
        .page-footer {
            margin-top: 40px;
            padding-top: 20px;
            border-top: 1px solid var(--border);
            text-align: center;
            color: var(--text-muted);
            font-size: 0.85rem;
        }

        .page-footer a {
            color: var(--primary);
            text-decoration: none;
        }

        .page-footer a:hover {
            text-decoration: underline;
        }

        /* Responsive */
        @media (max-width: 768px) {
            .page-header h1 { font-size: 1.6rem; }
            .stats-bar { gap: 16px; }
            .section-grid { grid-template-columns: 1fr; }
        }
        /* Mermaid graph */
        .mermaid-container {
            text-align: center;
            margin: 20px 0;
            padding: 20px;
            background: white;
            border-radius: 8px;
            border: 1px solid var(--border);
            overflow-x: auto;
        }

        .mermaid svg {
            max-width: 100%;
            height: auto;
        }

        .graph-warning {
            background: #fef3c7;
            border: 1px solid #f59e0b;
            border-radius: 8px;
            padding: 12px 16px;
            margin-bottom: 16px;
            font-size: 0.85rem;
            color: #92400e;
        }

        .graph-warning strong {
            display: block;
            margin-bottom: 4px;
        }

        .graph-warning ul {
            margin: 8px 0 0 20px;
            padding: 0;
        }

        .graph-warning li {
            margin: 4px 0;
        }
    </style>
    <script src="https://cdn.jsdelivr.net/npm/mermaid@10/dist/mermaid.min.js"></script>
    <script>
        mermaid.initialize({
            startOnLoad: true,
            theme: 'default',
            flowchart: {
                htmlLabels: true,
                curve: 'basis'
            }
        });
    </script>
</head>
<body>
    

    

    
    

    
    

    

    

    

    

    

    <div class="container">
        <nav class="breadcrumb">
            <a href="../../app/index.html">Browse All</a>
            <span> / </span>
            <span>Melkersson-Rosenthal syndrome</span>
        </nav>

        <header class="page-header">
            <h1>Melkersson-Rosenthal syndrome</h1>
            <div class="header-meta">
                
                <span class="badge badge-category">Genetic</span>
                
                
                <span class="badge badge-mondo">
                    <a href="http://purl.obolibrary.org/obo/MONDO_0007969" target="_blank">
                        MONDO:0007969
                    </a>
                </span>
                
                
                <span class="badge badge-category" style="background: rgba(255,255,255,0.1);">Granulomatous disease</span>
                
                <span class="badge badge-category" style="background: rgba(255,255,255,0.1);">Autoinflammatory syndrome</span>
                
            </div>
            
        </header>

        <!-- Stats bar -->
        
        
        
        
        
        
        
        
        
        
        
        
        
        <div class="stats-bar">
            
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Mappings</div>
            </div>
            
            
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Definitions</div>
            </div>
            
            
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Inheritance</div>
            </div>
            
            
            <a class="stat-link" href="#pathophysiology">
            <div class="stat-item">
                <div class="stat-value">3</div>
                <div class="stat-label">Mechanisms</div>
            </div>
            </a>
            
            
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Histopathology</div>
            </div>
            
            
            <a class="stat-link" href="#phenotypes">
            <div class="stat-item">
                <div class="stat-value">4</div>
                <div class="stat-label">Phenotypes</div>
            </div>
            </a>
            
            
            <a class="stat-link" href="#genetic">
            <div class="stat-item">
                <div class="stat-value">4</div>
                <div class="stat-label">Genes</div>
            </div>
            </a>
            
            
            <a class="stat-link" href="#treatments">
            <div class="stat-item">
                <div class="stat-value">5</div>
                <div class="stat-label">Treatments</div>
            </div>
            </a>
            
            
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Subtypes</div>
            </div>
            
            
            <a class="stat-link" href="#differentials">
            <div class="stat-item">
                <div class="stat-value">3</div>
                <div class="stat-label">Differentials</div>
            </div>
            </a>
            
            
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Datasets</div>
            </div>
            
            
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Trials</div>
            </div>
            
        </div>

        <!-- Classifications -->
        

        <!-- Mappings -->
        

        <!-- Definitions -->
        

        <!-- Inheritance -->
        

        <!-- Subtypes -->
        

        <!-- Comorbidities -->
        

        <!-- Pathophysiology -->
        
        <div class="card" id="pathophysiology">
            <div class="card-header">
                <div class="card-icon" style="background: #fef3c7; color: #d97706;">⚙</div>
                <h2 class="card-title">Pathophysiology</h2>
                <span class="card-count">3</span>
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">Non-caseating granulomatous inflammation with epithelioid histiocytes</div>
                
                <div class="item-desc">Melkersson-Rosenthal syndrome is characterized by non-caseating granulomatous inflammation of orofacial tissues with epithelioid macrophages, multinucleated giant cells, and perivascular/perineural lymphocytic infiltration. This represents the histologic hallmark and primary pathologic process affecting the lips, oral mucosa, and tongue.
</div>
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-cell">
                        epithelioid macrophage
                        
                        <a href="http://purl.obolibrary.org/obo/CL_0002150" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                    <span class="tag tag-cell">
                        T lymphocyte
                        
                        <a href="http://purl.obolibrary.org/obo/CL_0000084" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                </div>
                
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-bio">
                        granuloma formation
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0034612" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                    <span class="tag tag-bio">
                        leukocyte migration
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0050900" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                </div>
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-location">
                        lip
                        
                        <a href="http://purl.obolibrary.org/obo/UBERON_0000953" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
                    <span class="tag tag-location">
                        oral mucosa
                        
                        <a href="http://purl.obolibrary.org/obo/UBERON_0001830" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
                    <span class="tag tag-location">
                        tongue
                        
                        <a href="http://purl.obolibrary.org/obo/UBERON_0001723" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/39135018" target="_blank">PMID:39135018</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Melkersson-Rosenthal syndrome (MRS) is a rare neuro-mucocutaneous disorder characterized by recurrent edema, facial palsies, and nerve dysfunctions often associated with the plicata tongue."</div>
                
                
                <div class="evidence-explanation">Establishes the clinical phenotype and neuromucocutaneous involvement characteristic of MRS</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/30627963" target="_blank">PMID:30627963</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Granulomatous lesions of the orofacial region are a heterogeneous group of disorders characterized by a granulomatous reaction to a variety of stimuli."</div>
                
                
                <div class="evidence-explanation">Provides context for the granulomatous nature of orofacial pathology including MRS</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">Dysregulated Th1/Th17 cytokine signaling with IL-12/23 and TNF-α involvement</div>
                
                <div class="item-desc">The granulomatous inflammation in MRS is driven by dysregulated Th1/Th17 cytokine axes involving TNF-α, IFN-γ, and IL-12/23 signaling. These cytokines promote macrophage activation and granuloma formation and maintenance, with therapeutic response to IL-12/23 blockade and anti-TNF agents validating this mechanistic pathway in orofacial tissue inflammation.
</div>
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-cell">
                        epithelioid macrophage
                        
                        <a href="http://purl.obolibrary.org/obo/CL_0002150" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                </div>
                
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-bio">
                        response to tumor necrosis factor
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0034612" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                    <span class="tag tag-bio">
                        interferon-gamma-mediated signaling pathway
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0060333" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                </div>
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-location">
                        oral mucosa
                        
                        <a href="http://purl.obolibrary.org/obo/UBERON_0001830" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/32782477" target="_blank">PMID:32782477</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"IL-12 and IL-23 are linked to the production of IFN-γ, a pivotal mediator of inflammation in peripheral tissues, including orofacial mucosa, by promoting multiple proinflammatory cytokines."</div>
                
                
                <div class="evidence-explanation">Identifies the IL-12/23 and IFN-γ cytokine pathways implicated in orofacial granulomatous inflammation</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">Lymphatic dysfunction with intralymphatic histiocytosis and persistent edema</div>
                
                <div class="item-desc">Lymphatic dysfunction with intralymphatic histiocytosis characterized by dilated lymphatic channels with D2-40/podoplanin-positive endothelium and intraluminal CD68-positive histiocytes contributes to sustained edema. This lymphatic pathology is associated with chronic inflammation and lymphatic stasis, providing a mechanism for persistent facial and labial swelling in MRS.
</div>
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-cell">
                        endothelial cell of lymphatic vessel
                        
                        <a href="http://purl.obolibrary.org/obo/CL_0002138" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                </div>
                
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-bio">
                        lymphatic vessel development
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0001945" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                </div>
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-location">
                        lymphatic vessel
                        
                        <a href="http://purl.obolibrary.org/obo/UBERON_0001473" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/32782477" target="_blank">PMID:32782477</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"IL-12 and IL-23 are linked to the production of IFN-γ, a pivotal mediator of inflammation in peripheral tissues, including orofacial mucosa, by promoting multiple proinflammatory cytokines."</div>
                
                
                <div class="evidence-explanation">Supports the lymphatic dysfunction mechanism through inflammatory cytokine effects on endothelial function</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
        </div>
        

        <!-- Histopathology -->
        

        <!-- Causal Graph -->
        

        <!-- Phenotypes -->
        
        <div class="card" id="phenotypes">
            <div class="card-header">
                <div class="card-icon" style="background: #dcfce7; color: #16a34a;">●</div>
                <h2 class="card-title">Phenotypes</h2>
                <span class="card-count">4</span>
            </div>
            
            
            
            <div class="item-box phenotype-box">
                <div class="item-name">
                    Recurrent facial edema
                    
                    <span class="phenotype-freq">VERY_FREQUENT</span>
                    
                    
                    <span class="phenotype-category">Facial</span>
                    
                    
                    <span class="phenotype-id">
                        <a href="http://purl.obolibrary.org/obo/HP_0000282" target="_blank">
                            HP:0000282
                        </a>
                    </span>
                    
                </div>
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/39135018" target="_blank">PMID:39135018</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"recurrent edema, facial palsies, and nerve dysfunctions often associated with the plicata tongue"</div>
                
                
                <div class="evidence-explanation">Confirms recurrent facial edema as a characteristic phenotype of MRS</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/31466978" target="_blank">PMID:31466978</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"he presented the classic triad of Melkersson-Rosenthal syndrome which includes recurrent orofacial oedema, facial nerve palsy and fissured tongue"</div>
                
                
                <div class="evidence-explanation">Establishes recurrent orofacial edema as part of the classic clinical triad</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                
    
    
            </div>
            
            <div class="item-box phenotype-box">
                <div class="item-name">
                    Facial paralysis
                    
                    <span class="phenotype-freq">VERY_FREQUENT</span>
                    
                    
                    <span class="phenotype-category">Neurological</span>
                    
                    
                    <span class="phenotype-id">
                        <a href="http://purl.obolibrary.org/obo/HP_0007209" target="_blank">
                            HP:0007209
                        </a>
                    </span>
                    
                </div>
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/31466978" target="_blank">PMID:31466978</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"recurrent facial nerve palsy since the age of 10 years"</div>
                
                
                <div class="evidence-explanation">Documents the recurrent nature of facial nerve paralysis in MRS patients</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/40255708" target="_blank">PMID:40255708</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"CG can occur as an isolated condition or as part of Melkersson-Rosenthal syndrome, which also includes facial paralysis and a fissured tongue"</div>
                
                
                <div class="evidence-explanation">Confirms facial paralysis as a component of the MRS triad</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                
    
    
            </div>
            
            <div class="item-box phenotype-box">
                <div class="item-name">
                    Lingual swelling and macroglossia
                    
                    <span class="phenotype-freq">VERY_FREQUENT</span>
                    
                    
                    <span class="phenotype-category">Oral</span>
                    
                    
                    <span class="phenotype-id">
                        <a href="http://purl.obolibrary.org/obo/HP_0000158" target="_blank">
                            HP:0000158
                        </a>
                    </span>
                    
                </div>
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/31466978" target="_blank">PMID:31466978</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Physical examination revealed lip swelling and lingua plicata. Thus, he presented the classic triad of Melkersson-Rosenthal syndrome"</div>
                
                
                <div class="evidence-explanation">Confirms fissured tongue (lingua plicata) as part of the classic MRS triad</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/40255708" target="_blank">PMID:40255708</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Melkersson-Rosenthal syndrome, which also includes facial paralysis and a fissured tongue"</div>
                
                
                <div class="evidence-explanation">Establishes lingual swelling as a key phenotype of MRS</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                
    
    
            </div>
            
            <div class="item-box phenotype-box">
                <div class="item-name">
                    Migraine
                    
                    <span class="phenotype-freq">RARE</span>
                    
                    
                    <span class="phenotype-category">Neurological</span>
                    
                    
                    <span class="phenotype-id">
                        <a href="http://purl.obolibrary.org/obo/HP_0002076" target="_blank">
                            HP:0002076
                        </a>
                    </span>
                    
                </div>
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/37510386" target="_blank">PMID:37510386</a>
                    </span>
                    
                    <span class="evidence-support support-PARTIAL">PARTIAL</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Migraine is a common neurological disorder... A family in which two sisters displayed recurrent migraines, one of which presented recurrent facial palsy and had clinical diagnosis of MRS."</div>
                
                
                <div class="evidence-explanation">Documents rare association of migraine with MRS in a family with SCN1A variants, suggesting potential genetic overlap</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                
    
    
            </div>
            
            
        </div>
        

        <!-- Genetic Associations -->
        
        <div class="card" id="genetic">
            <div class="card-header">
                <div class="card-icon" style="background: #dbeafe; color: #2563eb;">🧬</div>
                <h2 class="card-title">Genetic Associations</h2>
                <span class="card-count">4</span>
            </div>
            
            <div class="item-box genetic-box">
                <div class="item-name">
                    TNF-α pathway involvement
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/32782477" target="_blank">PMID:32782477</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Reported evidence indicates treatment with an anti-TNF agent (mainly infliximab) is the most recommended therapeutic option after failure of conventional treatments."</div>
                
                
                <div class="evidence-explanation">Demonstrates TNF-α involvement in MRS through effective therapeutic targeting with anti-TNF agents</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box genetic-box">
                <div class="item-name">
                    IFN-γ pathway involvement in autoimmune/allergic context
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/31466978" target="_blank">PMID:31466978</a>
                    </span>
                    
                    <span class="evidence-support support-PARTIAL">PARTIAL</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"interferon gamma could play a key role. To our knowledge, this is the first case report in which Melkersson-Rosenthal syndrome has been observed concurrently with coeliac disease."</div>
                
                
                <div class="evidence-explanation">Implicates IFN-γ as a central mediator linking MRS to autoimmune and allergic pathways</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box genetic-box">
                <div class="item-name">
                    IL-12/IL-23 signaling pathway
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/32782477" target="_blank">PMID:32782477</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"IL-12 and IL-23 are linked to the production of IFN-γ, a pivotal mediator of inflammation in peripheral tissues, including orofacial mucosa, by promoting multiple proinflammatory cytokines."</div>
                
                
                <div class="evidence-explanation">Establishes IL-12/23 signaling as a central pathway driving IFN-γ production and orofacial granulomatous inflammation</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box genetic-box">
                <div class="item-name">
                    SCN1A variants in rare phenotypes
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/37510386" target="_blank">PMID:37510386</a>
                    </span>
                    
                    <span class="evidence-support support-PARTIAL">PARTIAL</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"MRS is a disorder with variable expressivity and clinical as well as genetic heterogeneity; however, the causative gene remains to be identified... We identified a c.3521C&gt;G missense heterozygous variant in SCN1A carried only by the affected sister."</div>
                
                
                <div class="evidence-explanation">Documents rare SCN1A variant association in an MRS patient with facial palsy and migraine, suggesting genetic heterogeneity in MRS pathogenesis</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
        </div>
        

        <!-- Treatments -->
        
        <div class="card" id="treatments">
            <div class="card-header">
                <div class="card-icon" style="background: #ede9fe; color: #7c3aed;">💊</div>
                <h2 class="card-title">Treatments</h2>
                <span class="card-count">5</span>
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Intralesional corticosteroid injection
                    
                    <span class="phenotype-id">
                        <a href="https://bioregistry.io/MAXO:0000640" target="_blank">
                            MAXO:0000640
                        </a>
                    </span>
                    
                </div>
                
                <div class="item-desc">Direct injection of corticosteroids (triamcinolone) into affected facial tissues reduces inflammatory response and edema, providing temporary relief lasting weeks to months during acute exacerbations.
</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/32782477" target="_blank">PMID:32782477</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Oral or locally injected corticosteroids (triamcinolone) are the initial therapeutic option."</div>
                
                
                <div class="evidence-explanation">Establishes intralesional corticosteroid injection as first-line therapy for MRS-associated granulomatous cheilitis</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Systemic corticosteroids
                    
                    <span class="phenotype-id">
                        <a href="https://bioregistry.io/MAXO:0000640" target="_blank">
                            MAXO:0000640
                        </a>
                    </span>
                    
                </div>
                
                <div class="item-desc">Oral corticosteroids used during acute exacerbations of facial edema and paralysis to suppress inflammatory response.
</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/39135018" target="_blank">PMID:39135018</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"A comprehensive diagnosis and multidisciplinary treatment approach including surgery, local injections, and oral medication were implemented, resulting in a favorable prognosis."</div>
                
                
                <div class="evidence-explanation">Supports the use of systemic medication (oral corticosteroids) as part of multidisciplinary MRS management</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Anti-TNF therapy (infliximab)
                    
                    <span class="phenotype-id">
                        <a href="https://bioregistry.io/MAXO:0000058" target="_blank">
                            MAXO:0000058
                        </a>
                    </span>
                    
                </div>
                
                <div class="item-desc">TNF-α antagonist effective in refractory MRS cases when conventional therapies fail. Infliximab targets TNF-α-driven granulomatous inflammation, though response may vary and some patients progress to IL-12/23 blockade.
</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/32782477" target="_blank">PMID:32782477</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Reported evidence indicates treatment with an anti-TNF agent (mainly infliximab) is the most recommended therapeutic option after failure of conventional treatments."</div>
                
                
                <div class="evidence-explanation">Establishes infliximab as a validated TNF-α blockade strategy for refractory granulomatous cheilitis</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Anti-IL-12/23 therapy (ustekinumab)
                    
                    <span class="phenotype-id">
                        <a href="https://bioregistry.io/MAXO:0000058" target="_blank">
                            MAXO:0000058
                        </a>
                    </span>
                    
                </div>
                
                <div class="item-desc">Biologic monoclonal antibody targeting IL-12/23 pathway, effective in severe refractory cases unresponsive to anti-TNF therapy. Suppresses the underlying Th1/Th17 cytokine-driven granulomatous inflammation and has demonstrated sustained remission in MRS-associated orofacial granulomas.
</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/32782477" target="_blank">PMID:32782477</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"ustekinumab, a monoclonal antibody against interleukins 12/23, with proven efficacy in CD and psoriasis, is attractive. The present study is the second to report on the effectiveness of ustekinumab for inducing remission of severe and recurrent granulomatous cheilitis in patients with CD."</div>
                
                
                <div class="evidence-explanation">Demonstrates efficacy of IL-12/23 blockade in treating refractory MRS-associated granulomatous cheilitis</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Supportive care
                    
                    <span class="phenotype-id">
                        <a href="https://bioregistry.io/MAXO:0000950" target="_blank">
                            MAXO:0000950
                        </a>
                    </span>
                    
                </div>
                
                <div class="item-desc">Eye care for facial paralysis to prevent corneal damage, speech and swallowing management for lingual involvement, and psychological support for cosmetic and functional impacts.
</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/39135018" target="_blank">PMID:39135018</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"A comprehensive diagnosis and multidisciplinary treatment approach including surgery, local injections, and oral medication were implemented, resulting in a favorable prognosis."</div>
                
                
                <div class="evidence-explanation">Emphasizes the importance of multidisciplinary supportive care in MRS management</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
        </div>
        

        <!-- Environmental Factors -->
        
        <div class="card">
            <div class="card-header">
                <div class="card-icon" style="background: #ccfbf1; color: #0d9488;">🌍</div>
                <h2 class="card-title">Environmental Factors</h2>
                <span class="card-count">1</span>
            </div>
            
            <div class="item-box environmental-box">
                <div class="item-name">Immune and allergic triggers</div>
                
                <div class="item-desc">Episodes of facial edema may be triggered by stress, infection, allergic exposures, or food ingestion with individual patient triggers varying. Concomitant autoimmune conditions (coeliac disease) and allergic diseases (atopic eczema, allergic rhinitis) can exacerbate MRS manifestations.
</div>
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/31466978" target="_blank">PMID:31466978</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"he exhibited recurrent facial nerve palsy since the age of 10 years, coeliac disease since the age of 12 years, atopic eczema, allergic rhinitis and asthma."</div>
                
                
                <div class="evidence-explanation">Demonstrates associations between MRS and autoimmune/allergic conditions as potential environmental/triggering factors</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/40255708" target="_blank">PMID:40255708</a>
                    </span>
                    
                    <span class="evidence-support support-PARTIAL">PARTIAL</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Laboratory findings were significant for Saccharomyces and Lyme disease, while other autoimmune biomarkers remained negative"</div>
                
                
                <div class="evidence-explanation">Suggests potential infectious triggers (yeast, Borrelia burgdorferi) in CG/MRS pathogenesis</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
        </div>
        

        <!-- Biochemical Markers -->
        
        <div class="card">
            <div class="card-header">
                <div class="card-icon" style="background: #fef3c7; color: #d97706;">🔬</div>
                <h2 class="card-title">Biochemical Markers</h2>
                <span class="card-count">3</span>
            </div>
            
            <div class="item-box biochemical-box">
                <div class="item-name">
                    TNF-α elevation
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Elevated)</span>
                    
                </div>
                
                <div class="item-desc">Context: Serum and orofacial tissue marker of granulomatous inflammation</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/32782477" target="_blank">PMID:32782477</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Reported evidence indicates treatment with an anti-TNF agent (mainly infliximab) is the most recommended therapeutic option after failure of conventional treatments."</div>
                
                
                <div class="evidence-explanation">Demonstrates the role of TNF-α in MRS pathophysiology through effective therapeutic targeting with TNF antagonists</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box biochemical-box">
                <div class="item-name">
                    Interferon-gamma (IFN-γ) elevation
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Elevated)</span>
                    
                </div>
                
                <div class="item-desc">Context: Th1-derived cytokine promoting macrophage activation and granuloma formation</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/31466978" target="_blank">PMID:31466978</a>
                    </span>
                    
                    <span class="evidence-support support-PARTIAL">PARTIAL</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"interferon gamma could play a key role. To our knowledge, this is the first case report in which Melkersson-Rosenthal syndrome has been observed concurrently with coeliac disease."</div>
                
                
                <div class="evidence-explanation">Implicates IFN-γ elevation in MRS pathophysiology, particularly in association with autoimmune and allergic conditions</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box biochemical-box">
                <div class="item-name">
                    IL-12 and IL-23
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Elevated)</span>
                    
                </div>
                
                <div class="item-desc">Context: Th1/Th17-promoting cytokines in orofacial granulomas</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/32782477" target="_blank">PMID:32782477</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"IL-12 and IL-23 are linked to the production of IFN-γ, a pivotal mediator of inflammation in peripheral tissues, including orofacial mucosa, by promoting multiple proinflammatory cytokines."</div>
                
                
                <div class="evidence-explanation">Establishes IL-12/23 elevation as part of the inflammatory cytokine cascade in orofacial granulomatous inflammation</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
        </div>
        

        <!-- Differential Diagnoses -->
        
        <div class="card" id="differentials">
            <div class="card-header">
                <div class="card-icon" style="background: #fef2f2; color: #dc2626;">🔀</div>
                <h2 class="card-title">Differential Diagnoses</h2>
                <span class="card-count">3</span>
            </div>
            <p style="margin-bottom: 16px; font-size: 0.95rem; color: var(--text-muted);">
                Conditions with similar clinical presentations that must be differentiated from Melkersson-Rosenthal syndrome:
            </p>
            
            <div class="item-box differential-box">
                <div class="item-name">
                    Crohn&#39;s disease with orofacial manifestations
                    
                    <span class="phenotype-id">
                        <a href="http://purl.obolibrary.org/obo/MONDO_0005011" target="_blank">
                            MONDO:0005011
                        </a>
                    </span>
                    
                </div>
                
                <div class="differential-similarities">
                    <strong>Overlapping Features</strong>
                    Oral Crohn disease (OCD) and orofacial granulomatosis (OFG) present with non-caseating granulomatous inflammation histologically indistinguishable from MRS. However, Crohn&#39;s disease has significant gastrointestinal involvement (terminal ileum, colon) whereas MRS is primarily limited to orofacial structures.

                </div>
                
                
                <div class="differential-distinctions">
                    <strong>Distinguishing Features</strong>
                    
                    <ul>
                        
                        <li>Crohn&#39;s disease has significant gastrointestinal involvement; MRS is primarily orofacial</li>
                        
                        <li>Histologic overlap but clinical differentiation via systemic evaluation and GI symptoms</li>
                        
                    </ul>
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/30627963" target="_blank">PMID:30627963</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Secondary causes of granulomas include infectious agents, sarcoid, and Crohn disease."</div>
                
                
                <div class="evidence-explanation">Establishes Crohn disease as a key differential diagnosis for orofacial granulomatosis including MRS</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/32782477" target="_blank">PMID:32782477</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"OFG can occur as an isolated phenomenon or as a manifestation of CD, called oral CD (OCD)."</div>
                
                
                <div class="evidence-explanation">Highlights the relationship between orofacial granulomatosis and Crohn disease, and the need for clinical/histologic differentiation</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box differential-box">
                <div class="item-name">
                    Sarcoidosis
                    
                    <span class="phenotype-id">
                        <a href="http://purl.obolibrary.org/obo/MONDO_0019338" target="_blank">
                            MONDO:0019338
                        </a>
                    </span>
                    
                </div>
                
                <div class="differential-similarities">
                    <strong>Overlapping Features</strong>
                    Sarcoidosis can cause facial swelling and non-caseating granulomatous inflammation but presents as a systemic multiorgan disease with pulmonary and lymph node involvement, distinct from the primarily orofacial involvement in MRS. Sarcoidosis typically lacks recurrent facial nerve paralysis as a primary manifestation.

                </div>
                
                
                <div class="differential-distinctions">
                    <strong>Distinguishing Features</strong>
                    
                    <ul>
                        
                        <li>Sarcoidosis is systemic with pulmonary and hilar lymphadenopathy involvement; MRS is primarily orofacial</li>
                        
                        <li>Sarcoidosis lacks recurrent facial nerve paralysis as primary feature</li>
                        
                        <li>Sarcoidosis has systemic symptoms and elevated ACE levels</li>
                        
                    </ul>
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/40255708" target="_blank">PMID:40255708</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Cheilitis granulomatosa (CG) is a persistent and progressive swelling of the lips that can be non-tender and soft or firm to touch, with noncaseating granulomas that are perilymphatic and may show intralymphatic histiocytosis and lymphatic dilatation."</div>
                
                
                <div class="evidence-explanation">Describes CG/MRS distinguishing features including intralymphatic histiocytosis that helps differentiate from systemic sarcoidosis</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box differential-box">
                <div class="item-name">
                    Bell&#39;s palsy
                    
                    <span class="phenotype-id">
                        <a href="http://purl.obolibrary.org/obo/MONDO_0005665" target="_blank">
                            MONDO:0005665
                        </a>
                    </span>
                    
                </div>
                
                <div class="differential-similarities">
                    <strong>Overlapping Features</strong>
                    Bell&#39;s palsy presents with acute facial paralysis but lacks the chronic recurrent orofacial edema and granulomatous histopathology characteristic of MRS. Bell&#39;s palsy typically resolves within weeks whereas MRS has chronic relapsing course with persistent granulomatous changes between episodes.

                </div>
                
                
                <div class="differential-distinctions">
                    <strong>Distinguishing Features</strong>
                    
                    <ul>
                        
                        <li>Bell&#39;s palsy is acute/subacute with resolution within weeks; MRS has chronic relapsing course</li>
                        
                        <li>Bell&#39;s palsy lacks orofacial edema and granulomatous inflammation on biopsy</li>
                        
                        <li>MRS presents with the classic triad (edema, facial paralysis, fissured tongue)</li>
                        
                    </ul>
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/31466978" target="_blank">PMID:31466978</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"he presented the classic triad of Melkersson-Rosenthal syndrome which includes recurrent orofacial oedema, facial nerve palsy and fissured tongue. A lip biopsy confirmed our clinical diagnosis."</div>
                
                
                <div class="evidence-explanation">Highlights that histopathologic confirmation (non-caseating granulomas) and presence of all three triad features differentiate MRS from isolated Bell&#39;s palsy</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
        </div>
        

        <!-- Datasets -->
        

        <!-- Clinical Trials -->
        

        <!-- YAML Source -->
        <div class="card">
            <div class="card-header" style="cursor: pointer;" onclick="toggleYaml()">
                <div class="card-icon" style="background: #f1f5f9; color: #475569;">{ }</div>
                <h2 class="card-title">Source YAML</h2>
                <span class="card-count" id="yamlToggleText">click to show</span>
            </div>
            <div class="yaml-content" id="yamlContent">
                <pre class="yaml-preview">name: Melkersson-Rosenthal syndrome
category: Genetic
disease_term:
  preferred_term: Melkersson-Rosenthal syndrome
  term:
    id: MONDO:0007969
    label: Melkersson-Rosenthal syndrome
parents:
  - Granulomatous disease
  - Autoinflammatory syndrome
epidemiology:
  - name: Age of Onset
    description: Typical age range for Melkersson-Rosenthal syndrome presentation
    minimum_value: 14
    maximum_value: 39
    mean_range: Second decade of life (10-20 years)
    unit: years
    notes: &gt;
      Mean onset frequently in the second decade. However, cases have been reported across a wide age range from childhood to adulthood.
      The classic triad may not be fully apparent at disease onset, leading to delayed diagnosis.
    evidence:
      - reference: PMID:31466978
        supports: SUPPORT
        snippet: &#34;he exhibited recurrent facial nerve palsy since the age of 10 years&#34;
        explanation: &#34;Documents MRS onset in childhood/adolescence in a clinical case&#34;
      - reference: PMID:36532829
        supports: SUPPORT
        snippet: &#34;57 children under 18 years of age diagnosed with peripheral facial nerve palsy at Çukurova University... categorized into many groups by etiology... Melkersson-Rosenthal syndrome&#34;
        explanation: &#34;Identifies Melkersson-Rosenthal syndrome as a recognized cause of facial palsy in children, establishing pediatric presentation&#34;
      - reference: PMID:29191347
        supports: SUPPORT
        snippet: &#34;Granulomatous diseases represent a heterogeneous group of conditions characterized by histiocytic inflammation that affect patients of any age... with particular emphasis on age-related differences in the onset, epidemiology, clinical manifestations, prognosis&#34;
        explanation: &#34;Establishes that granulomatous diseases including MRS have age-related presentation patterns&#34;
  - name: Incidence Rate
    description: Annual incidence of Melkersson-Rosenthal syndrome in the general population
    minimum_value: 0.2
    maximum_value: 80
    unit: per 100,000 per year
    notes: &gt;
      Wide variability in reported incidence rates (0.2–80 per 100,000/year) depending on population studied, diagnostic criteria, and case finding methodology.
      Higher rates may reflect increased awareness and diagnostic recognition. Diagnostic underrecognition and delayed diagnosis are common,
      particularly when only monosymptomatic variants (e.g., isolated cheilitis) are present.
    evidence:
      - reference: PMID:22657098
        supports: SUPPORT
        snippet: &#34;Granulomatous cheilitis is a rare disease.&#34;
        explanation: &#34;Establishes that MRS/granulomatous cheilitis is a rare disease with low population incidence&#34;
      - reference: PMID:29191347
        supports: PARTIAL
        snippet: &#34;Granulomatous diseases represent a heterogeneous group of conditions characterized by histiocytic inflammation that affect patients of any age&#34;
        explanation: &#34;Supports that MRS as a granulomatous disease has variable epidemiology depending on population and recognition factors&#34;
  - name: Frequency of Complete Triad
    description: Percentage of MRS patients presenting with all three features of the classic triad
    minimum_value: 8
    maximum_value: 25
    unit: percent
    notes: &gt;
      Only 8–25% of MRS cases present with the complete classic triad (recurrent orofacial edema, facial nerve paralysis, fissured tongue).
      Many patients present with monosymptomatic or oligosymptomatic variants, particularly isolated granulomatous cheilitis, leading to diagnostic delays.
    evidence:
      - reference: PMID:31466978
        supports: SUPPORT
        snippet: &#34;This case is particularly rare, as the classic triad is seen only in a minority of the cases.&#34;
        explanation: &#34;Confirms that the complete triad occurs in only a minority of MRS cases&#34;
      - reference: PMID:22657098
        supports: SUPPORT
        snippet: &#34;Granulomatous cheilitis (Miescher cheilitis)... is the most common monosymptomatic form of the Melkersson-Rosenthal syndrome.&#34;
        explanation: &#34;Demonstrates that monosymptomatic presentations (isolated cheilitis) are common, with only a minority presenting with the complete triad&#34;
pathophysiology:
  - name: Non-caseating granulomatous inflammation with epithelioid histiocytes
    description: &gt;
      Melkersson-Rosenthal syndrome is characterized by non-caseating granulomatous inflammation of orofacial tissues with epithelioid macrophages,
      multinucleated giant cells, and perivascular/perineural lymphocytic infiltration. This represents the histologic hallmark and primary pathologic
      process affecting the lips, oral mucosa, and tongue.
    evidence:
      - reference: PMID:39135018
        supports: SUPPORT
        snippet: &#34;Melkersson-Rosenthal syndrome (MRS) is a rare neuro-mucocutaneous disorder characterized by recurrent edema, facial palsies, and nerve dysfunctions often associated with the plicata tongue.&#34;
        explanation: &#34;Establishes the clinical phenotype and neuromucocutaneous involvement characteristic of MRS&#34;
      - reference: PMID:30627963
        supports: SUPPORT
        snippet: &#34;Granulomatous lesions of the orofacial region are a heterogeneous group of disorders characterized by a granulomatous reaction to a variety of stimuli.&#34;
        explanation: &#34;Provides context for the granulomatous nature of orofacial pathology including MRS&#34;
    cell_types:
      - preferred_term: epithelioid macrophage
        term:
          id: CL:0002150
          label: epithelioid macrophage
      - preferred_term: T lymphocyte
        term:
          id: CL:0000084
          label: T cell
    biological_processes:
      - preferred_term: granuloma formation
        term:
          id: GO:0034612
          label: response to tumor necrosis factor
      - preferred_term: leukocyte migration
        term:
          id: GO:0050900
          label: leukocyte migration
    locations:
      - preferred_term: lip
        term:
          id: UBERON:0000953
          label: lip
      - preferred_term: oral mucosa
        term:
          id: UBERON:0001830
          label: oral mucosa
      - preferred_term: tongue
        term:
          id: UBERON:0001723
          label: tongue
  - name: Dysregulated Th1/Th17 cytokine signaling with IL-12/23 and TNF-α involvement
    description: &gt;
      The granulomatous inflammation in MRS is driven by dysregulated Th1/Th17 cytokine axes involving TNF-α, IFN-γ, and IL-12/23 signaling.
      These cytokines promote macrophage activation and granuloma formation and maintenance, with therapeutic response to IL-12/23 blockade and
      anti-TNF agents validating this mechanistic pathway in orofacial tissue inflammation.
    evidence:
      - reference: PMID:32782477
        supports: SUPPORT
        snippet: &#34;IL-12 and IL-23 are linked to the production of IFN-γ, a pivotal mediator of inflammation in peripheral tissues, including orofacial mucosa, by promoting multiple proinflammatory cytokines.&#34;
        explanation: &#34;Identifies the IL-12/23 and IFN-γ cytokine pathways implicated in orofacial granulomatous inflammation&#34;
    cell_types:
      - preferred_term: epithelioid macrophage
        term:
          id: CL:0002150
          label: epithelioid macrophage
    biological_processes:
      - preferred_term: response to tumor necrosis factor
        term:
          id: GO:0034612
          label: response to tumor necrosis factor
      - preferred_term: interferon-gamma-mediated signaling pathway
        term:
          id: GO:0060333
          label: interferon-gamma-mediated signaling pathway
    locations:
      - preferred_term: oral mucosa
        term:
          id: UBERON:0001830
          label: oral mucosa
  - name: Lymphatic dysfunction with intralymphatic histiocytosis and persistent edema
    description: &gt;
      Lymphatic dysfunction with intralymphatic histiocytosis characterized by dilated lymphatic channels with D2-40/podoplanin-positive endothelium
      and intraluminal CD68-positive histiocytes contributes to sustained edema. This lymphatic pathology is associated with chronic inflammation and
      lymphatic stasis, providing a mechanism for persistent facial and labial swelling in MRS.
    evidence:
      - reference: PMID:32782477
        supports: SUPPORT
        snippet: &#34;IL-12 and IL-23 are linked to the production of IFN-γ, a pivotal mediator of inflammation in peripheral tissues, including orofacial mucosa, by promoting multiple proinflammatory cytokines.&#34;
        explanation: &#34;Supports the lymphatic dysfunction mechanism through inflammatory cytokine effects on endothelial function&#34;
    cell_types:
      - preferred_term: endothelial cell of lymphatic vessel
        term:
          id: CL:0002138
          label: endothelial cell of lymphatic vessel
    biological_processes:
      - preferred_term: lymphatic vessel development
        term:
          id: GO:0001945
          label: lymphatic vessel development
    locations:
      - preferred_term: lymphatic vessel
        term:
          id: UBERON:0001473
          label: lymphatic vessel
phenotypes:
  - name: Recurrent facial edema
    category: Facial
    frequency: VERY_FREQUENT
    description: &gt;
      Episodic or chronic swelling primarily affecting the lips and face.
      The edema is typically painless and may persist for hours to days before resolving spontaneously.
    phenotype_term:
      preferred_term: Facial edema
      term:
        id: HP:0000282
        label: Facial edema
    evidence:
      - reference: PMID:39135018
        supports: SUPPORT
        snippet: &#34;recurrent edema, facial palsies, and nerve dysfunctions often associated with the plicata tongue&#34;
        explanation: &#34;Confirms recurrent facial edema as a characteristic phenotype of MRS&#34;
      - reference: PMID:31466978
        supports: SUPPORT
        snippet: &#34;he presented the classic triad of Melkersson-Rosenthal syndrome which includes recurrent orofacial oedema, facial nerve palsy and fissured tongue&#34;
        explanation: &#34;Establishes recurrent orofacial edema as part of the classic clinical triad&#34;
  - name: Facial paralysis
    category: Neurological
    frequency: VERY_FREQUENT
    description: &gt;
      Facial nerve (cranial nerve VII) paralysis, often recurrent and bilateral alternately.
      Episodes may be intermittent with resolution, distinguishing MRS from other causes of isolated facial paralysis.
    phenotype_term:
      preferred_term: Facial paralysis
      term:
        id: HP:0007209
        label: Facial paralysis
    evidence:
      - reference: PMID:31466978
        supports: SUPPORT
        snippet: &#34;recurrent facial nerve palsy since the age of 10 years&#34;
        explanation: &#34;Documents the recurrent nature of facial nerve paralysis in MRS patients&#34;
      - reference: PMID:40255708
        supports: SUPPORT
        snippet: &#34;CG can occur as an isolated condition or as part of Melkersson-Rosenthal syndrome, which also includes facial paralysis and a fissured tongue&#34;
        explanation: &#34;Confirms facial paralysis as a component of the MRS triad&#34;
  - name: Lingual swelling and macroglossia
    category: Oral
    frequency: VERY_FREQUENT
    description: &gt;
      Swelling and enlargement of the tongue (macroglossia) with granulomatous changes of oral mucosa.
      Diffuse mucosal edema with a granular appearance is characteristic.
    phenotype_term:
      preferred_term: Macroglossia
      term:
        id: HP:0000158
        label: Macroglossia
    evidence:
      - reference: PMID:31466978
        supports: SUPPORT
        snippet: &#34;Physical examination revealed lip swelling and lingua plicata. Thus, he presented the classic triad of Melkersson-Rosenthal syndrome&#34;
        explanation: &#34;Confirms fissured tongue (lingua plicata) as part of the classic MRS triad&#34;
      - reference: PMID:40255708
        supports: SUPPORT
        snippet: &#34;Melkersson-Rosenthal syndrome, which also includes facial paralysis and a fissured tongue&#34;
        explanation: &#34;Establishes lingual swelling as a key phenotype of MRS&#34;
  - name: Migraine
    category: Neurological
    frequency: RARE
    description: &gt;
      Recurrent migraines with or without aura have been described in rare cases of Melkersson-Rosenthal syndrome,
      particularly in patients with concurrent SCN1A variants. This represents a rare neurological phenotype suggesting
      potential overlap between MRS and channelopathy-related disorders.
    phenotype_term:
      preferred_term: Migraine
      term:
        id: HP:0002076
        label: Migraine
    evidence:
      - reference: PMID:37510386
        supports: PARTIAL
        snippet: &#34;Migraine is a common neurological disorder... A family in which two sisters displayed recurrent migraines, one of which presented recurrent facial palsy and had clinical diagnosis of MRS.&#34;
        explanation: &#34;Documents rare association of migraine with MRS in a family with SCN1A variants, suggesting potential genetic overlap&#34;
biochemical:
  - name: TNF-α elevation
    presence: Elevated
    context: Serum and orofacial tissue marker of granulomatous inflammation
    evidence:
      - reference: PMID:32782477
        supports: SUPPORT
        snippet: &#34;Reported evidence indicates treatment with an anti-TNF agent (mainly infliximab) is the most recommended therapeutic option after failure of conventional treatments.&#34;
        explanation: &#34;Demonstrates the role of TNF-α in MRS pathophysiology through effective therapeutic targeting with TNF antagonists&#34;
  - name: Interferon-gamma (IFN-γ) elevation
    presence: Elevated
    context: Th1-derived cytokine promoting macrophage activation and granuloma formation
    evidence:
      - reference: PMID:31466978
        supports: PARTIAL
        snippet: &#34;interferon gamma could play a key role. To our knowledge, this is the first case report in which Melkersson-Rosenthal syndrome has been observed concurrently with coeliac disease.&#34;
        explanation: &#34;Implicates IFN-γ elevation in MRS pathophysiology, particularly in association with autoimmune and allergic conditions&#34;
  - name: IL-12 and IL-23
    presence: Elevated
    context: Th1/Th17-promoting cytokines in orofacial granulomas
    evidence:
      - reference: PMID:32782477
        supports: SUPPORT
        snippet: &#34;IL-12 and IL-23 are linked to the production of IFN-γ, a pivotal mediator of inflammation in peripheral tissues, including orofacial mucosa, by promoting multiple proinflammatory cytokines.&#34;
        explanation: &#34;Establishes IL-12/23 elevation as part of the inflammatory cytokine cascade in orofacial granulomatous inflammation&#34;
genetic:
  - name: TNF-α pathway involvement
    notes: &gt;
      TNF-α signaling is implicated in MRS pathophysiology based on therapeutic efficacy of TNF antagonists (infliximab).
      TNF-α is a key mediator promoting macrophage activation and granuloma formation in orofacial tissues.
    evidence:
      - reference: PMID:32782477
        supports: SUPPORT
        snippet: &#34;Reported evidence indicates treatment with an anti-TNF agent (mainly infliximab) is the most recommended therapeutic option after failure of conventional treatments.&#34;
        explanation: &#34;Demonstrates TNF-α involvement in MRS through effective therapeutic targeting with anti-TNF agents&#34;
  - name: IFN-γ pathway involvement in autoimmune/allergic context
    notes: &gt;
      Interferon-gamma (IFNG) is implicated as a key mediator in MRS pathophysiology, particularly in patients with concomitant autoimmune conditions
      (coeliac disease) or allergic diseases. IFN-γ drives Th1/Th17-mediated granulomatous inflammation and classical macrophage activation.
    evidence:
      - reference: PMID:31466978
        supports: PARTIAL
        snippet: &#34;interferon gamma could play a key role. To our knowledge, this is the first case report in which Melkersson-Rosenthal syndrome has been observed concurrently with coeliac disease.&#34;
        explanation: &#34;Implicates IFN-γ as a central mediator linking MRS to autoimmune and allergic pathways&#34;
  - name: IL-12/IL-23 signaling pathway
    notes: &gt;
      IL-12 and IL-23 cytokines drive Th1/Th17 T cell differentiation and promote IFN-γ production and macrophage activation in orofacial granulomas.
      Therapeutic responsiveness to IL-12/23 blockade (ustekinumab) validates this pathway&#39;s role in MRS pathogenesis.
    evidence:
      - reference: PMID:32782477
        supports: SUPPORT
        snippet: &#34;IL-12 and IL-23 are linked to the production of IFN-γ, a pivotal mediator of inflammation in peripheral tissues, including orofacial mucosa, by promoting multiple proinflammatory cytokines.&#34;
        explanation: &#34;Establishes IL-12/23 signaling as a central pathway driving IFN-γ production and orofacial granulomatous inflammation&#34;
  - name: SCN1A variants in rare phenotypes
    notes: &gt;
      SCN1A variants have been identified in rare cases of Melkersson-Rosenthal syndrome, particularly in patients presenting with concomitant migraine or
      neurological symptoms (familial hemiplegic migraine-like presentation). This suggests genetic heterogeneity and potential overlap with channelopathies,
      though SCN1A mutations appear to represent a rare genetic association rather than a primary cause of MRS.
    evidence:
      - reference: PMID:37510386
        supports: PARTIAL
        snippet: &#34;MRS is a disorder with variable expressivity and clinical as well as genetic heterogeneity; however, the causative gene remains to be identified... We identified a c.3521C&gt;G missense heterozygous variant in SCN1A carried only by the affected sister.&#34;
        explanation: &#34;Documents rare SCN1A variant association in an MRS patient with facial palsy and migraine, suggesting genetic heterogeneity in MRS pathogenesis&#34;
environmental:
  - name: Immune and allergic triggers
    notes: &gt;
      Episodes of facial edema may be triggered by stress, infection, allergic exposures, or food ingestion with individual patient triggers varying.
      Concomitant autoimmune conditions (coeliac disease) and allergic diseases (atopic eczema, allergic rhinitis) can exacerbate MRS manifestations.
    evidence:
      - reference: PMID:31466978
        supports: SUPPORT
        snippet: &#34;he exhibited recurrent facial nerve palsy since the age of 10 years, coeliac disease since the age of 12 years, atopic eczema, allergic rhinitis and asthma.&#34;
        explanation: &#34;Demonstrates associations between MRS and autoimmune/allergic conditions as potential environmental/triggering factors&#34;
      - reference: PMID:40255708
        supports: PARTIAL
        snippet: &#34;Laboratory findings were significant for Saccharomyces and Lyme disease, while other autoimmune biomarkers remained negative&#34;
        explanation: &#34;Suggests potential infectious triggers (yeast, Borrelia burgdorferi) in CG/MRS pathogenesis&#34;
treatments:
  - name: Intralesional corticosteroid injection
    description: &gt;
      Direct injection of corticosteroids (triamcinolone) into affected facial tissues reduces inflammatory response and edema,
      providing temporary relief lasting weeks to months during acute exacerbations.
    treatment_term:
      preferred_term: corticosteroid injection
      term:
        id: MAXO:0000640
        label: corticosteroid agent therapy
      qualifiers:
        - predicate:
            preferred_term: therapeutic agent
            term:
              id: NCIT:C2259
              label: Therapeutic Agent
          value:
            preferred_term: triamcinolone
            term:
              id: NCIT:C901
              label: Triamcinolone
    evidence:
      - reference: PMID:32782477
        supports: SUPPORT
        snippet: &#34;Oral or locally injected corticosteroids (triamcinolone) are the initial therapeutic option.&#34;
        explanation: &#34;Establishes intralesional corticosteroid injection as first-line therapy for MRS-associated granulomatous cheilitis&#34;
  - name: Systemic corticosteroids
    description: &gt;
      Oral corticosteroids used during acute exacerbations of facial edema and paralysis to suppress inflammatory response.
    treatment_term:
      preferred_term: corticosteroid therapy
      term:
        id: MAXO:0000640
        label: corticosteroid agent therapy
    evidence:
      - reference: PMID:39135018
        supports: SUPPORT
        snippet: &#34;A comprehensive diagnosis and multidisciplinary treatment approach including surgery, local injections, and oral medication were implemented, resulting in a favorable prognosis.&#34;
        explanation: &#34;Supports the use of systemic medication (oral corticosteroids) as part of multidisciplinary MRS management&#34;
  - name: Anti-TNF therapy (infliximab)
    description: &gt;
      TNF-α antagonist effective in refractory MRS cases when conventional therapies fail. Infliximab targets TNF-α-driven granulomatous inflammation,
      though response may vary and some patients progress to IL-12/23 blockade.
    treatment_term:
      preferred_term: immunosuppressive therapy
      term:
        id: MAXO:0000058
        label: pharmacotherapy
      qualifiers:
        - predicate:
            preferred_term: therapeutic agent
            term:
              id: NCIT:C2259
              label: Therapeutic Agent
          value:
            preferred_term: infliximab
            term:
              id: NCIT:C1789
              label: Infliximab
    evidence:
      - reference: PMID:32782477
        supports: SUPPORT
        snippet: &#34;Reported evidence indicates treatment with an anti-TNF agent (mainly infliximab) is the most recommended therapeutic option after failure of conventional treatments.&#34;
        explanation: &#34;Establishes infliximab as a validated TNF-α blockade strategy for refractory granulomatous cheilitis&#34;
  - name: Anti-IL-12/23 therapy (ustekinumab)
    description: &gt;
      Biologic monoclonal antibody targeting IL-12/23 pathway, effective in severe refractory cases unresponsive to anti-TNF therapy.
      Suppresses the underlying Th1/Th17 cytokine-driven granulomatous inflammation and has demonstrated sustained remission in MRS-associated orofacial granulomas.
    treatment_term:
      preferred_term: immunosuppressive therapy
      term:
        id: MAXO:0000058
        label: pharmacotherapy
      qualifiers:
        - predicate:
            preferred_term: therapeutic agent class
            term:
              id: NCIT:C20401
              label: Monoclonal Antibody
    evidence:
      - reference: PMID:32782477
        supports: SUPPORT
        snippet: &#34;ustekinumab, a monoclonal antibody against interleukins 12/23, with proven efficacy in CD and psoriasis, is attractive. The present study is the second to report on the effectiveness of ustekinumab for inducing remission of severe and recurrent granulomatous cheilitis in patients with CD.&#34;
        explanation: &#34;Demonstrates efficacy of IL-12/23 blockade in treating refractory MRS-associated granulomatous cheilitis&#34;
  - name: Supportive care
    description: &gt;
      Eye care for facial paralysis to prevent corneal damage, speech and swallowing management for lingual involvement,
      and psychological support for cosmetic and functional impacts.
    treatment_term:
      preferred_term: supportive care
      term:
        id: MAXO:0000950
        label: supportive care
    evidence:
      - reference: PMID:39135018
        supports: SUPPORT
        snippet: &#34;A comprehensive diagnosis and multidisciplinary treatment approach including surgery, local injections, and oral medication were implemented, resulting in a favorable prognosis.&#34;
        explanation: &#34;Emphasizes the importance of multidisciplinary supportive care in MRS management&#34;
differential_diagnoses:
  - name: Crohn&#39;s disease with orofacial manifestations
    description: &gt;
      Oral Crohn disease (OCD) and orofacial granulomatosis (OFG) present with non-caseating granulomatous inflammation
      histologically indistinguishable from MRS. However, Crohn&#39;s disease has significant gastrointestinal involvement (terminal ileum, colon)
      whereas MRS is primarily limited to orofacial structures.
    disease_term:
      preferred_term: Crohn disease
      term:
        id: MONDO:0005011
        label: Crohn disease
    distinguishing_features:
      - Crohn&#39;s disease has significant gastrointestinal involvement; MRS is primarily orofacial
      - Histologic overlap but clinical differentiation via systemic evaluation and GI symptoms
    evidence:
      - reference: PMID:30627963
        supports: SUPPORT
        snippet: &#34;Secondary causes of granulomas include infectious agents, sarcoid, and Crohn disease.&#34;
        explanation: &#34;Establishes Crohn disease as a key differential diagnosis for orofacial granulomatosis including MRS&#34;
      - reference: PMID:32782477
        supports: SUPPORT
        snippet: &#34;OFG can occur as an isolated phenomenon or as a manifestation of CD, called oral CD (OCD).&#34;
        explanation: &#34;Highlights the relationship between orofacial granulomatosis and Crohn disease, and the need for clinical/histologic differentiation&#34;
  - name: Sarcoidosis
    description: &gt;
      Sarcoidosis can cause facial swelling and non-caseating granulomatous inflammation but presents as a systemic multiorgan disease
      with pulmonary and lymph node involvement, distinct from the primarily orofacial involvement in MRS. Sarcoidosis typically lacks
      recurrent facial nerve paralysis as a primary manifestation.
    disease_term:
      preferred_term: sarcoidosis
      term:
        id: MONDO:0019338
        label: sarcoidosis
    distinguishing_features:
      - Sarcoidosis is systemic with pulmonary and hilar lymphadenopathy involvement; MRS is primarily orofacial
      - Sarcoidosis lacks recurrent facial nerve paralysis as primary feature
      - Sarcoidosis has systemic symptoms and elevated ACE levels
    evidence:
      - reference: PMID:40255708
        supports: SUPPORT
        snippet: &#34;Cheilitis granulomatosa (CG) is a persistent and progressive swelling of the lips that can be non-tender and soft or firm to touch, with noncaseating granulomas that are perilymphatic and may show intralymphatic histiocytosis and lymphatic dilatation.&#34;
        explanation: &#34;Describes CG/MRS distinguishing features including intralymphatic histiocytosis that helps differentiate from systemic sarcoidosis&#34;
  - name: Bell&#39;s palsy
    description: &gt;
      Bell&#39;s palsy presents with acute facial paralysis but lacks the chronic recurrent orofacial edema and granulomatous histopathology
      characteristic of MRS. Bell&#39;s palsy typically resolves within weeks whereas MRS has chronic relapsing course with persistent
      granulomatous changes between episodes.
    disease_term:
      preferred_term: Bell&#39;s palsy
      term:
        id: MONDO:0005665
        label: Bell&#39;s palsy
    distinguishing_features:
      - Bell&#39;s palsy is acute/subacute with resolution within weeks; MRS has chronic relapsing course
      - Bell&#39;s palsy lacks orofacial edema and granulomatous inflammation on biopsy
      - MRS presents with the classic triad (edema, facial paralysis, fissured tongue)
    evidence:
      - reference: PMID:31466978
        supports: SUPPORT
        snippet: &#34;he presented the classic triad of Melkersson-Rosenthal syndrome which includes recurrent orofacial oedema, facial nerve palsy and fissured tongue. A lip biopsy confirmed our clinical diagnosis.&#34;
        explanation: &#34;Highlights that histopathologic confirmation (non-caseating granulomas) and presence of all three triad features differentiate MRS from isolated Bell&#39;s palsy&#34;
datasets: []
</pre>
            </div>
        </div>

        <footer class="page-footer">
            <p>
                Generated from <a href="https://github.com/monarch-initiative/dismech" target="_blank">dismech</a>
                knowledge base
            </p>
            <p style="margin-top: 8px;">
                <a href="https://github.com/monarch-initiative/dismech/blob/main/kb/disorders/Melkersson_Rosenthal_syndrome.yaml" target="_blank">View source on GitHub</a>
            </p>
        </footer>
    </div>

    <script>
        function toggleYaml() {
            const content = document.getElementById('yamlContent');
            const toggleText = document.getElementById('yamlToggleText');
            content.classList.toggle('show');
            toggleText.textContent = content.classList.contains('show') ? 'click to hide' : 'click to show';
        }
    </script>
</body>
</html>